Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 27 (16) 2638-2644
Year:
2009
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA052352, U10 CA037417, U10 CA035269, CA-37404, U10 CA060276, CA-52352, CA-35195, U10 CA037404, U10 CA063848, U10 CA035195, CA-35103, CA-25224, CA-60276, U10 CA035272, U10 CA035101, P30 CA015083, CA-63848, U10 CA035415, U10 CA063849, CA-63826, CA-35415, CA-37417, CA-35272, CA-35269, CA-35101, U10 CA025224, CA-15083, CA-63849, N01 CA015083, U10 CA035103  
Corr. Author:
 
Authors:
                           
Networks:
 
Study
NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Bc3, Bc4, Bc5, Original Reports, Breast Cancer